Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of Mirabegron and Tolterodine
NCT01964183Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2013
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirabegron in overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoints: Plasma concentration of unchanged mirabegron at Day 14 and Plasma concentration of unchanged tolterodine at Day 14. Started Jun 2013; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01964183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964183.